A study of LN-145 for the treatment of cervical cancer.

Trial Profile

A study of LN-145 for the treatment of cervical cancer.

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs LN 145 (Primary)
  • Indications Cervical cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Jun 2017 According to an Iovance Biotherapeutics media release, Lion Biotechnologies has changed its name to Iovance Biotherapeutics.
    • 01 Feb 2016 Status changed from planning to not yet recruiting, as reported by Lion Biotechnologies Inc media release.
    • 01 Feb 2016 According to a Lion Biotechnologies Inc media release, the US Food and Drug Administration (FDA) has allowed its investigational new drug (IND) application to conduct this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top